Preliminary screening and analysis of metastasis‑related lncRNA and co‑expressed papillary thyroid carcinoma mRNA

Ge,Ming‑Hua; Jiang,Lie‑Hao; Wen,Qing‑Liang; Tan,Zhuo; Chen,Chao; Zheng,Chuan‑Ming; Zhu,Xin; Chen,Jia‑Wen; Zhu,Zi‑Yu; Cai,Xiu‑Jun

doi:10.3892/ol.2018.9080

Preliminary screening and analysis of metastasis‑related lncRNA and co‑expressed papillary thyroid carcinoma mRNA

Authors:
- Ming‑Hua Ge
- Lie‑Hao Jiang
- Qing‑Liang Wen
- Zhuo Tan
- Chao Chen
- Chuan‑Ming Zheng
- Xin Zhu
- Jia‑Wen Chen
- Zi‑Yu Zhu
- Xiu‑Jun Cai
View Affiliations

Affiliations: Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China, Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310016, P.R. China, Donghai Science and Technology College, Zhejiang Ocean University, Zhoushan, Zhejiang 316000, P.R. China, School of Stomatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310016, P.R. China, Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China
Published online on: July 5, 2018 https://doi.org/10.3892/ol.2018.9080
Pages: 3715-3725
Copyright: © Ge et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to investigate the long non‑coding RNA (lncRNA) and mRNA expression profiles that are associated with the invasion and metastasis of papillary thyroid carcinoma (PTC). Transwell invasion assays were used to screen three highly invasive sub‑strains of the human PTC IHH4 cell line: IHH4‑M1, IHH4‑M2 and IHH4‑M3. In addition, tumor‑bearing nude mice were used to identify the invasive and metastatic capacity of the three sub‑strains. Agilent lncRNA microarray chips were used to screen 795 differentially expressed lncRNAs and 788 differentially expressed mRNAs. A total of 10 lncRNAs and 10 mRNAs were randomly selected for RT‑qPCR validation to confirm that the results were consistent with the microarray chips, suggesting that the results of the microarray chip analysis were relatively accurate. Gene ontology enrichment‑based cluster analysis revealed that the differentially expressed genes were mainly associated with steroid biosynthesis, bioadhesion, intercellular adhesion and other metastasis‑associated biological processes. The results of the pathway cluster analysis identified that the differentially expressed genes were associated with tumor metastasis‑associated signaling pathways, including the cholesterol metabolic signaling pathway, the sterol regulatory element‑binding protein signaling pathway and the integrin signaling pathway, suggesting that lncRNA may regulate PTC metastasis through various signaling pathways. The present study screened and constructed PTC metastasis‑associated lncRNA and mRNA expression profiles, and it provides a molecular basis for the future study of high‑risk molecular markers of PTC.

View Figures

View References

1	Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2014. National Cancer Institute; Bethesda, MD: https://seer.cancer.gov/csr/1975_2014/based on November 2016 SEER data submission, posted to the SEER web site. April. 2017
2	Davies L and Welch HG: Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
4	Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F and Schlumberger M: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
5	American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, . Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ito Y and Miyauchi A: Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol. 27:15–20. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H and Takanashi Y: Lymph node metastasis from 259 papillary thyroid microcarcinomas: Frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 237:399–407. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
9	Sun W, Wu Y, Yu X, Liu Y, Song H, Xia T, Xiao B and Guo J: Decreased expression of long noncoding RNA AC096655.1-002 in gastric cancer and its clinical significance. Tumour Biol. 34:2697–2701. 2013. View Article : Google Scholar : PubMed/NCBI
10	Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, Liu YW, Zhang EB, Liu XH and De W: Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer. 14:3192014. View Article : Google Scholar : PubMed/NCBI
11	Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H and Jia W: Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol. 30:5882013. View Article : Google Scholar : PubMed/NCBI
12	Qiao HP, Gao WS, Huo JX and Yang ZS: Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian Pac J Cancer Prev. 14:1077–1082. 2013. View Article : Google Scholar : PubMed/NCBI
13	Liu JH, Chen G, Dang YW, Li CJ and Luo DZ: Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. Asian Pac J Cancer Prev. 15:2971–2977. 2014. View Article : Google Scholar : PubMed/NCBI
14	Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM and Patel T: microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene. 30:4750–4756. 2011. View Article : Google Scholar : PubMed/NCBI
15	Lv N, Shan Z, Gao Y, Guan H, Fan C, Wang H and Teng W: Twist1 regulates the epithelial-mesenchymal transition via the NF-kB pathway in papillary thyroid carcinoma. Endocrine. 51:469–477. 2016. View Article : Google Scholar : PubMed/NCBI
16	Leboulleux S, Tuttle RM, Pacini F and Schlumberger M: Papillary thyroid microcarcinoma: Time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 4:933–942. 2016. View Article : Google Scholar : PubMed/NCBI
17	Fan YH, Ding J, Nguyen S, Liu XJ, Xu G, Zhou HY, Duan NN, Yang SM, Zern MA and Wu J: Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells. Oncogene. 35:116–124. 2016. View Article : Google Scholar : PubMed/NCBI
18	Huang C: Abstract 426: Suppression of cell invasion and migration by inhibitors to ROS level in human lung cancer cells. Cancer Res. 70:426. 2010. View Article : Google Scholar
19	Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF and Mischel PS: Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest. 84:8–20. 2004. View Article : Google Scholar : PubMed/NCBI
20	William S: Guidance document on the recognition, assessment, and use of clinical signs as humane endpoints for experimental animals used in safety evaluation. OECD Environmental Health and Safety Publications, Series on Testing and Assessment 19; 2000
21	Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao W, Fang H, Kawasaki ES, Hager J, Tikhonova IR, et al: Performance comparison of one-color and two-color platforms within the MicroArray quality control (MAQC) project. Nat Biotechnol. 24:1140–1150. 2006. View Article : Google Scholar : PubMed/NCBI
22	Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Xing M, Haugen BR and Schlumberger M: Progress in molecular-based management of differentiated thyroid cancer. Lancet. 381:1058–1069. 2013. View Article : Google Scholar : PubMed/NCBI
25	Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW and Xing M: Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: Genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. Sep 1–2016.(Epub ahead of print).
26	Carr FE, Tai PW, Barnum MS, Gillis NE, Evans KG, Taber TH, White JH, Tomczak JA, Jaworski DM, Zaidi SK, et al: Thyroid hormone receptor-β (TRβ) mediates runt-related transcription factor 2 (Run×2) expression in thyroid cancer cells: A novel signaling pathway in thyroid cancer. Endocrinology. 157:3278–3292. 2016. View Article : Google Scholar : PubMed/NCBI
27	Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, Jung YY, Oh YL, Yim HS, Kim YL, et al: Diffuse sclerosing variant of papillary thyroid carcinoma: Major genetic alterations and prognostic implications. Histopathology. 69:45–53. 2016. View Article : Google Scholar : PubMed/NCBI
28	Sidaway P: Thyroid cancer: BRAF and/or TERT mutations increase mortality. Nat Rev Clin Oncol. 13:6522016. View Article : Google Scholar
29	Gupta Chandra S and Tripathi Nandan Y: Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967. 2017. View Article : Google Scholar : PubMed/NCBI
30	Gibb EA, Brown CJ and Lam WL: The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
31	Eades G, Zhang YS, Li QL, Xia JX, Yao Y and Zhou Q: Long non-coding RNAs in stem cells and cancer. World J Clin Oncol. 5:134–141. 2014. View Article : Google Scholar : PubMed/NCBI
32	Moran VA, Perera RJ and Khalil AM: Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 40:6391–6400. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yoon H, He H, Nagy R, Davuluri R, Suster S, Schoenberg D, Pellegata N and Ade Chapelle L: Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int J Cancer. 121:767–775. 2007. View Article : Google Scholar : PubMed/NCBI
34	Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu J and Sun Y: BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 8:1947–1952. 2014. View Article : Google Scholar : PubMed/NCBI